دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
“Timing is Everything�: the evolving role of immune checkpoint inhibition in nasopharyngeal carcinoma
A. J. Rosenberg & E. E. Vokes*
doi : 10.1016/j.annonc.2023.01.007
Volume 34, Issue 3, March 2023, Pages 213-214
Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations
Z. Kuzbari1y, C. Bandlamudi2y, C. Loveday 1 , A. Garrett1 , M. Mehine2 , A. George1,3 , H. Hanson 1,4 , K. Snape 4 , A. Kulkarni 5 , S. Allen 1 , S. Jezdic6 , R. Ferrandino6 , C. B. Westphalen 7 , E. Castro 8 , J. Rodon9 , J. Mateo10,11 , G. J. Burghel12 , M. F. Berger2 , D. Mandelker 2y & C. Turnbull
doi : 10.1016/j.annonc.2022.12.003
Volume 34, Issue 3, March 2023, Pages 215-227
Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A. Krämer1,2 , T. Bochtler 1,2,3 , C. Pauli 4,5 , G. Baciarello6 , S. Delorme 7 , K. Hemminki8,9 , L. Mileshkin 10 , H. Moch 4,5 , K. Oien11 , T. Olivier 12,13 , A. Patrikidou 14 , H. Wasan 15 , G. Zarkavelis16 , G. Pentheroudakis 17 & K. Fizazi 14 , on behalf of the ESMO Guidelines Committee
doi : 10.1016/j.annonc.2022.11.013
Volume 34, Issue 3, March 2023, Pages 228-246
ESMO–EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent/metastatic disease
P. Bossi 1 , A. T. Chan 2 , C. Even3 & J.-P. Machiels 4,5 , on behalf of the ESMO Guidelines Committee *
doi : 10.1016/j.annonc.2022.11.011
Volume 34, Issue 3, March 2023, Pages 247-250
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
A. T. C. Chan 1* , V. H. F. Lee2 , R.-L. Hong 3 , M.-J. Ahn4 , W. Q. Chong 5 , S.-B. Kim 6 , G. F. Ho7 , P. B. Caguioa 8 , N. Ngamphaiboon 9 , C. Ho 10 , M. A. S. A. Aziz 11 , Q. S. Ng12 , C.-J. Yen 13 , N. Soparattanapaisarn 14 , R. K.-C. Ngan 15 , S. K. Kho 16 , M. L. A. Tiambeng 17 , T. Yun18 , V. Sriuranpong19 , A. P. Algazi 20 , A. Cheng 21 , E. Massarelli 22 , R. F. Swaby 23 , S. Saraf 23 , J. Yuan 23 & L. L. Siu
doi : 10.1016/j.annonc.2022.12.007
Volume 34, Issue 3, March 2023, Pages 251-261
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
A. Psyrri1* , J. Fayette 2 , K. Harrington3 , M. Gillison 4 , M.-J. Ahn5 , S. Takahashi6 , J. Weiss 7 , J.-P. Machiels8,9 , S. Baxi 10 , A. Vasilyev 11 , A. Karpenko 12 , M. Dvorkin 13 , C.-Y. Hsieh14 , S. C. Thungappa 15 , P. P. Segura16 , I. Vynnychenko 17 , R. Haddad18 , S. Kasper19 , P.-S. Mauz20 , V. Baker21 , P. He 22 , B. Evans 22 , S. Wildsmith21 , R. F. Olsson 23 , A. Yovine 21 , J. F. Kurland 24 , N. Morsli 21 & T. Y. Seiwert 25* , for the KESTREL Investigators
doi : 10.1016/j.annonc.2022.12.008
Volume 34, Issue 3, March 2023, Pages 262-274
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma
S. Scalera 1y, B. Ricciuti 2y, M. Mazzotta 3y, N. Calonaci 4 , J. V. Alessi 2 , L. Cipriani 1 , G. Bon5 , B. Messina 6 , G. Lamberti 2 , A. Di Federico2 , F. Pecci2 , S. Milite4 , E. Krasniqi 7 , M. Barba 7 , P. Vici 8 , A. Vecchione 9 , F. De Nicola1 , L. Ciuffreda 1 , F. Goeman 1 , M. Fanciulli 1 , S. Buglioni 10 , E. Pescarmona10 , B. Sharma 11 , K. D. Felt11 , J. Lindsay12 , S. J. Rodig 11,13 , R. De Maria 14,15 , G. Caravagna4 , F. Cappuzzo 7 , G. Ciliberto 16 , M. M. Awad2z & M. Maugeri-SaccÃ
doi : 10.1016/j.annonc.2022.12.002
Volume 34, Issue 3, March 2023, Pages 275-288
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
A. V. Balar1 , D. E. Castellano 2 , P. Grivas 3 , D. J. Vaughn4 , T. Powles 5 , J. Vuky 6 , Y. Fradet7 , J.-L. Lee8 , L. Fong 9 , N. J. Vogelzang 10y, M. A. Climent 11 , A. Necchi 12 , D. P. Petrylak13 , E. R. Plimack14 , J. Z. Xu 15 , K. Imai15 , B. H. Moreno 15 , J. Bellmunt16 , R. de Wit17* & P. H. O’Donnell
doi : 10.1016/j.annonc.2022.11.012
Volume 34, Issue 3, March 2023, Pages 289-299
Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy
K. White 1yz, K. Connor1yz, M. Meylan2 , A. Bougoüin2 , M. Salvucci 1y, F. Bielle 3y, A. C. O’Farrell 1y, K. Sweeney4 , L. Weng5y, G. Bergers5y, P. Dicker 6 , D. M. Ashley 7 , E. S. Lipp 7 , J. T. Low 7 , J. Zhao8 , P. Wen 9 , R. Prins10 , M. Verreault 3y, A. Idbaih 11y, A. Biswas 1y, J. H. M. Prehn1y, D. Lambrechts 12,13y, I. Arijs 12,13y, F. Lodi12,13y, G. Dilcan 12,13y, M. Lamfers14y, S. Leenstra 14y, F. Fabro 14y, I. Ntafoulis 14y, J. M. Kros15 , J. Cryan 16 , F. Brett16 , E. Quissac 3 , A. Beausang16 , S. MacNally 4 , P. O’Halloran4 , J. Clerkin 4 , O. Bacon16 , A. Kremer17y, R. T. Chi Yen17y, F. S. Varn 18 , R. G. W. Verhaak 18,19 , C. Sautès-Fridman 2y, W. H. Fridman 2y & A. T. Byrne
doi : 10.1016/j.annonc.2022.11.008
Volume 34, Issue 3, March 2023, Pages 300-314
Excellent response to olaparib in metastatic HR-positive, HER2-negative breast cancer with BRIP1 mutation
D. Kwapisz 1,2 *, B. Verret3 , C. Garcia 4 & F. André
doi : 10.1016/j.annonc.2023.01.012
Volume 34, Issue 3, March 2023, Pages 315-318
VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
S. Y. Rha 1, L. S. Wyrwicz 2 , P. E. Y. Weber 3 , Y. Bai 4 , M. H. Ryu 5 , J. Lee 6 , F. Rivera7 , G. V. Alves 8 , M. Garrido 9 , K-K. Shiu 10 , M. González Fernández 11 , J. Li 12 , M. Lowery 13 , T. Cil 14 , F. J. S. M. Cruz 15 , S. Qin 16 , L. Yin 17 , S. Bordia18 , P. Bhagia 18 & D-Y. Oh
doi : 10.1016/j.annonc.2023.01.006
Volume 34, Issue 3, March 2023, Pages 319-320
Corrigendum to “23P - The correlations between knowledge and attitudes of productive age women toward “SADARI� (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali�: [Annals of Oncology volume 30, supplement 9 (2019) abstract 23P: ix7]
I. B. Y. Brahmantya1* , A. B. S. Satyarsa2 , S. A. A. Suryantari2 , K. D. Puspitasari 1 & A. T. Adiputra 3
doi : 10.1016/j.annonc.2022.06.001
Volume 34, Issue 3, March 2023, Page 321
Corrigendum to “Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation�: [Annals of Oncology 28 (2017):2503–2510]
H. Takamatsu 1* , N. Takezako 2 , J. Zheng3 , M. Moorhead3 , V. E. H. Carlton 3 , K. A. Kong 3 , R. Murata 4 , S. Ito5 , T. Miyamoto6 , K. Yokoyama 7 , K. Matsue 8 , T. Sato 9 , T. Kurokawa10 , H. Yagi 11 , Y. Terasaki12 , K. Ohata 1 , M. Matsumoto 13 , T. Yoshida14 , M. Faham 3 & S. Nakao
doi : 10.1016/j.annonc.2022.08.004
Volume 34, Issue 3, March 2023, Page 322
Corrigendum to “MO10-6 miR-4647 an early biomarker of outcome in chronic myeloid leukaemia patients�: [Annals of Oncology 33 suppl. 6 (2022) S488]
S. A. Guru 1 , M. P. Sumi2 , I. A. Najar3 , A. R. Mir 4 & A. Saxena
doi : 10.1016/j.annonc.2022.08.082
Volume 34, Issue 3, March 2023, Page 323
Corrigendum to “12P The efficacy of EGFR tyrosine kinase inhibitors and its clinical prognostic factors in lung adenocarcinoma patients harboring different types of EGFR mutations: Real-world data�: [Annals of Oncology volume 33, supplement 8 (2022) S1387–S1388]
R. Vicente* , M. Vitorino, R. Ferreira & A. Chaves
doi : 10.1016/j.annonc.2022.11.001
Volume 34, Issue 3, March 2023, Page 324
Corrigendum to “Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up�: [Annals of Oncology 31 (2020) 17–29]
E. Zucca1,2,3 , L. Arcaini 4,5 , C. Buske 6 , P. W. Johnson 7 , M. Ponzoni8 , M. Raderer9 , U. Ricardi 10 , A. Salar 11 , K. Stamatopoulos 12 , C. Thieblemont 13 , A. Wotherspoon 14 & M. Ladetto 15 , on behalf of the ESMO Guidelines Committee
doi : 10.1016/j.annonc.2022.11.009
Volume 34, Issue 3, March 2023, Page 325
Corrigendum to “Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer�: [Annals of Oncology 33 (2022) 769–785]
K. Van Baelen 1,2 , T. Geukens1,3 , M. Maetens 1 , V. Tjan-Heijnen4 , C. J. Lord 5 , S. Linn 6,7,8 , F.-C. Bidard9 , F. Richard1 , W. W. Yang 5 , R. E. Steele 5 , S. J. Pettitt 5 , C. Van Ongeval 10 , M. De Schepper 1,11 , E. Isnaldi1 , I. Nevelsteen 12 , A. Smeets 12 , K. Punie3 , L. Voorwerk13,14 , H. Wildiers 3 , G. Floris 11 , A. Vincent Salomon15 , P. W. B. Derksen6 , P. Neven2 , E. Senkus 16 , E. Sawyer17 , M. Kok 13,14 & C. Desmedt
doi : 10.1016/j.annonc.2022.11.010
Volume 34, Issue 3, March 2023, Page 326
“Timing is Everything�: the evolving role of immune checkpoint inhibition in nasopharyngeal carcinoma
A. J. Rosenberg & E. E. Vokes*
doi : 10.1016/j.annonc.2023.01.007
Volume 34, Issue 3, March 2023, Pages 213-214
Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations
Z. Kuzbari1y, C. Bandlamudi2y, C. Loveday 1 , A. Garrett1 , M. Mehine2 , A. George1,3 , H. Hanson 1,4 , K. Snape 4 , A. Kulkarni 5 , S. Allen 1 , S. Jezdic6 , R. Ferrandino6 , C. B. Westphalen 7 , E. Castro 8 , J. Rodon9 , J. Mateo10,11 , G. J. Burghel12 , M. F. Berger2 , D. Mandelker 2y & C. Turnbull
doi : 10.1016/j.annonc.2022.12.003
Volume 34, Issue 3, March 2023, Pages 215-227
Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A. Krämer1,2 , T. Bochtler 1,2,3 , C. Pauli 4,5 , G. Baciarello6 , S. Delorme 7 , K. Hemminki8,9 , L. Mileshkin 10 , H. Moch 4,5 , K. Oien11 , T. Olivier 12,13 , A. Patrikidou 14 , H. Wasan 15 , G. Zarkavelis16 , G. Pentheroudakis 17 & K. Fizazi 14 , on behalf of the ESMO Guidelines Committee
doi : 10.1016/j.annonc.2022.11.013
Volume 34, Issue 3, March 2023, Pages 228-246
ESMO–EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent/metastatic disease
P. Bossi 1 , A. T. Chan 2 , C. Even3 & J.-P. Machiels 4,5 , on behalf of the ESMO Guidelines Committee *
doi : 10.1016/j.annonc.2022.11.011
Volume 34, Issue 3, March 2023, Pages 247-250
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
A. T. C. Chan 1* , V. H. F. Lee2 , R.-L. Hong 3 , M.-J. Ahn4 , W. Q. Chong 5 , S.-B. Kim 6 , G. F. Ho7 , P. B. Caguioa 8 , N. Ngamphaiboon 9 , C. Ho 10 , M. A. S. A. Aziz 11 , Q. S. Ng12 , C.-J. Yen 13 , N. Soparattanapaisarn 14 , R. K.-C. Ngan 15 , S. K. Kho 16 , M. L. A. Tiambeng 17 , T. Yun18 , V. Sriuranpong19 , A. P. Algazi 20 , A. Cheng 21 , E. Massarelli 22 , R. F. Swaby 23 , S. Saraf 23 , J. Yuan 23 & L. L. Siu
doi : 10.1016/j.annonc.2022.12.007
Volume 34, Issue 3, March 2023, Pages 251-261
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
A. Psyrri1* , J. Fayette 2 , K. Harrington3 , M. Gillison 4 , M.-J. Ahn5 , S. Takahashi6 , J. Weiss 7 , J.-P. Machiels8,9 , S. Baxi 10 , A. Vasilyev 11 , A. Karpenko 12 , M. Dvorkin 13 , C.-Y. Hsieh14 , S. C. Thungappa 15 , P. P. Segura16 , I. Vynnychenko 17 , R. Haddad18 , S. Kasper19 , P.-S. Mauz20 , V. Baker21 , P. He 22 , B. Evans 22 , S. Wildsmith21 , R. F. Olsson 23 , A. Yovine 21 , J. F. Kurland 24 , N. Morsli 21 & T. Y. Seiwert 25* , for the KESTREL Investigators
doi : 10.1016/j.annonc.2022.12.008
Volume 34, Issue 3, March 2023, Pages 262-274
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma
S. Scalera 1y, B. Ricciuti 2y, M. Mazzotta 3y, N. Calonaci 4 , J. V. Alessi 2 , L. Cipriani 1 , G. Bon5 , B. Messina 6 , G. Lamberti 2 , A. Di Federico2 , F. Pecci2 , S. Milite4 , E. Krasniqi 7 , M. Barba 7 , P. Vici 8 , A. Vecchione 9 , F. De Nicola1 , L. Ciuffreda 1 , F. Goeman 1 , M. Fanciulli 1 , S. Buglioni 10 , E. Pescarmona10 , B. Sharma 11 , K. D. Felt11 , J. Lindsay12 , S. J. Rodig 11,13 , R. De Maria 14,15 , G. Caravagna4 , F. Cappuzzo 7 , G. Ciliberto 16 , M. M. Awad2z & M. Maugeri-SaccÃ
doi : 10.1016/j.annonc.2022.12.002
Volume 34, Issue 3, March 2023, Pages 275-288
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
A. V. Balar1 , D. E. Castellano 2 , P. Grivas 3 , D. J. Vaughn4 , T. Powles 5 , J. Vuky 6 , Y. Fradet7 , J.-L. Lee8 , L. Fong 9 , N. J. Vogelzang 10y, M. A. Climent 11 , A. Necchi 12 , D. P. Petrylak13 , E. R. Plimack14 , J. Z. Xu 15 , K. Imai15 , B. H. Moreno 15 , J. Bellmunt16 , R. de Wit17* & P. H. O’Donnell
doi : 10.1016/j.annonc.2022.11.012
Volume 34, Issue 3, March 2023, Pages 289-299
Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy
K. White 1yz, K. Connor1yz, M. Meylan2 , A. Bougoüin2 , M. Salvucci 1y, F. Bielle 3y, A. C. O’Farrell 1y, K. Sweeney4 , L. Weng5y, G. Bergers5y, P. Dicker 6 , D. M. Ashley 7 , E. S. Lipp 7 , J. T. Low 7 , J. Zhao8 , P. Wen 9 , R. Prins10 , M. Verreault 3y, A. Idbaih 11y, A. Biswas 1y, J. H. M. Prehn1y, D. Lambrechts 12,13y, I. Arijs 12,13y, F. Lodi12,13y, G. Dilcan 12,13y, M. Lamfers14y, S. Leenstra 14y, F. Fabro 14y, I. Ntafoulis 14y, J. M. Kros15 , J. Cryan 16 , F. Brett16 , E. Quissac 3 , A. Beausang16 , S. MacNally 4 , P. O’Halloran4 , J. Clerkin 4 , O. Bacon16 , A. Kremer17y, R. T. Chi Yen17y, F. S. Varn 18 , R. G. W. Verhaak 18,19 , C. Sautès-Fridman 2y, W. H. Fridman 2y & A. T. Byrne
doi : 10.1016/j.annonc.2022.11.008
Volume 34, Issue 3, March 2023, Pages 300-314
Excellent response to olaparib in metastatic HR-positive, HER2-negative breast cancer with BRIP1 mutation
D. Kwapisz 1,2 *, B. Verret3 , C. Garcia 4 & F. André
doi : 10.1016/j.annonc.2023.01.012
Volume 34, Issue 3, March 2023, Pages 315-318
VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
S. Y. Rha 1, L. S. Wyrwicz 2 , P. E. Y. Weber 3 , Y. Bai 4 , M. H. Ryu 5 , J. Lee 6 , F. Rivera7 , G. V. Alves 8 , M. Garrido 9 , K-K. Shiu 10 , M. González Fernández 11 , J. Li 12 , M. Lowery 13 , T. Cil 14 , F. J. S. M. Cruz 15 , S. Qin 16 , L. Yin 17 , S. Bordia18 , P. Bhagia 18 & D-Y. Oh
doi : 10.1016/j.annonc.2023.01.006
Volume 34, Issue 3, March 2023, Pages 319-320
Corrigendum to “23P - The correlations between knowledge and attitudes of productive age women toward “SADARI� (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali�: [Annals of Oncology volume 30, supplement 9 (2019) abstract 23P: ix7]
I. B. Y. Brahmantya1* , A. B. S. Satyarsa2 , S. A. A. Suryantari2 , K. D. Puspitasari 1 & A. T. Adiputra 3
doi : 10.1016/j.annonc.2022.06.001
Volume 34, Issue 3, March 2023, Page 321
Corrigendum to “Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation�: [Annals of Oncology 28 (2017):2503–2510]
H. Takamatsu 1* , N. Takezako 2 , J. Zheng3 , M. Moorhead3 , V. E. H. Carlton 3 , K. A. Kong 3 , R. Murata 4 , S. Ito5 , T. Miyamoto6 , K. Yokoyama 7 , K. Matsue 8 , T. Sato 9 , T. Kurokawa10 , H. Yagi 11 , Y. Terasaki12 , K. Ohata 1 , M. Matsumoto 13 , T. Yoshida14 , M. Faham 3 & S. Nakao
doi : 10.1016/j.annonc.2022.08.004
Volume 34, Issue 3, March 2023, Page 322
Corrigendum to “MO10-6 miR-4647 an early biomarker of outcome in chronic myeloid leukaemia patients�: [Annals of Oncology 33 suppl. 6 (2022) S488]
S. A. Guru 1 , M. P. Sumi2 , I. A. Najar3 , A. R. Mir 4 & A. Saxena
doi : 10.1016/j.annonc.2022.08.082
Volume 34, Issue 3, March 2023, Page 323
Corrigendum to “12P The efficacy of EGFR tyrosine kinase inhibitors and its clinical prognostic factors in lung adenocarcinoma patients harboring different types of EGFR mutations: Real-world data�: [Annals of Oncology volume 33, supplement 8 (2022) S1387–S1388]
R. Vicente* , M. Vitorino, R. Ferreira & A. Chaves
doi : 10.1016/j.annonc.2022.11.001
Volume 34, Issue 3, March 2023, Page 324
Corrigendum to “Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up�: [Annals of Oncology 31 (2020) 17–29]
E. Zucca1,2,3 , L. Arcaini 4,5 , C. Buske 6 , P. W. Johnson 7 , M. Ponzoni8 , M. Raderer9 , U. Ricardi 10 , A. Salar 11 , K. Stamatopoulos 12 , C. Thieblemont 13 , A. Wotherspoon 14 & M. Ladetto 15 , on behalf of the ESMO Guidelines Committee
doi : 10.1016/j.annonc.2022.11.009
Volume 34, Issue 3, March 2023, Page 325
Corrigendum to “Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer�: [Annals of Oncology 33 (2022) 769–785]
K. Van Baelen 1,2 , T. Geukens1,3 , M. Maetens 1 , V. Tjan-Heijnen4 , C. J. Lord 5 , S. Linn 6,7,8 , F.-C. Bidard9 , F. Richard1 , W. W. Yang 5 , R. E. Steele 5 , S. J. Pettitt 5 , C. Van Ongeval 10 , M. De Schepper 1,11 , E. Isnaldi1 , I. Nevelsteen 12 , A. Smeets 12 , K. Punie3 , L. Voorwerk13,14 , H. Wildiers 3 , G. Floris 11 , A. Vincent Salomon15 , P. W. B. Derksen6 , P. Neven2 , E. Senkus 16 , E. Sawyer17 , M. Kok 13,14 & C. Desmedt
doi : 10.1016/j.annonc.2022.11.010
Volume 34, Issue 3, March 2023, Page 326
